Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Cash & Equivalents (2022 - 2026)

Compass Therapeutics' Cash & Equivalents history spans 5 years, with the latest figure at $55.2 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents rose 32.56% to $55.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $55.2 million, a 32.56% increase, with the full-year FY2025 number at $31.2 million, down 29.15% from a year prior.
  • Cash & Equivalents hit $55.2 million in Q1 2026 for Compass Therapeutics, up from $31.2 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for CMPX hit a ceiling of $55.2 million in Q1 2026 and a floor of $19.3 million in Q2 2023.
  • Historically, Cash & Equivalents has averaged $32.8 million across 5 years, with a median of $30.8 million in 2023.
  • Biggest five-year swings in Cash & Equivalents: plummeted 36.23% in 2024 and later surged 138.16% in 2025.
  • Tracing CMPX's Cash & Equivalents over 5 years: stood at $34.9 million in 2022, then crashed by 30.58% to $24.2 million in 2023, then skyrocketed by 81.82% to $44.1 million in 2024, then fell by 29.15% to $31.2 million in 2025, then soared by 76.76% to $55.2 million in 2026.
  • Business Quant data shows Cash & Equivalents for CMPX at $55.2 million in Q1 2026, $31.2 million in Q4 2025, and $46.2 million in Q3 2025.